NCT07413263Not yet recruiting
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 27 Nov 2025
- Start date
- 1 May 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07413263
What you commit to
- Study type: Observational
- Planned participants: 75
- From 1 May 2026 to the primary completion date, 30 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- diabetic
Who the study is looking for
- CML patients free medical history
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.